{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:31:32Z","timestamp":1794087092941,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"RS Oncology LLC, Cambridge MA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75153-y","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:03:03Z","timestamp":1784019783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6629-5167","authenticated-orcid":false,"given":"Victoria","family":"Gibson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-7687","authenticated-orcid":false,"given":"Joanna","family":"Dzialo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Messier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-4905","authenticated-orcid":false,"given":"Aleksandra","family":"Bzura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Poile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens C.","family":"Hahne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Habibovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0933-9065","authenticated-orcid":false,"given":"Stephanie","family":"Stead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Saaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Szlosarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-5609","authenticated-orcid":false,"given":"Simon","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-7008","authenticated-orcid":false,"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4363-8492","authenticated-orcid":false,"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Nakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wells-Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kudzayi","family":"Kutywayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Butnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas. H.","family":"Heintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Naumov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0762-1726","authenticated-orcid":false,"given":"Maurice","family":"Dungey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4243-0724","authenticated-orcid":false,"given":"Julio Herrero","family":"Colomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-4895","authenticated-orcid":false,"given":"Burak","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Dulloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-8491","authenticated-orcid":false,"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-1312","authenticated-orcid":false,"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-2134","authenticated-orcid":false,"given":"Brian","family":"Cunniff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"75153_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","volume":"136","author":"J Luo","year":"2009","unstructured":"Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823\u2013837 (2009).","journal-title":"Cell"},{"key":"75153_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1749-6632.2009.05039.x","volume":"1177","author":"F Weinberg","year":"2009","unstructured":"Weinberg, F. & Chandel, N. S. Mitochondrial metabolism and cancer. Ann. N. Y Acad. Sci. 1177, 66\u201373 (2009).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"75153_CR3","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00018-009-0099-y","volume":"66","author":"F Weinberg","year":"2009","unstructured":"Weinberg, F. & Chandel, N. S. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol. Life Sci. 66, 3663\u20133673 (2009).","journal-title":"Cell Mol. Life Sci."},{"key":"75153_CR4","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","volume":"24","author":"M Schieber","year":"2014","unstructured":"Schieber, M. & Chandel, N. S. ROS function in redox signaling and oxidative stress. Curr. Biol. 24, R453\u2013R462 (2014).","journal-title":"Curr. Biol."},{"key":"75153_CR5","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes, S. M., Alrifai, D. & Fennell, D. A. Perspectives on the treatment of malignant pleural mesothelioma. N. Engl. J. Med 385, 1207\u20131218 (2021).","journal-title":"N. Engl. J. Med"},{"key":"75153_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41420-023-01307-2","volume":"9","author":"H Yang","year":"2023","unstructured":"Yang, H. et al. MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell Death Discov. 9, 55 (2023).","journal-title":"Cell Death Discov."},{"key":"75153_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41416-019-0661-9","volume":"122","author":"L Urso","year":"2020","unstructured":"Urso, L. et al. Metabolic rewiring and redox alterations in malignant pleural mesothelioma. Br. J. Cancer 122, 52\u201361 (2020).","journal-title":"Br. J. Cancer"},{"key":"75153_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931\u2013947 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"75153_CR9","doi-asserted-by":"publisher","first-page":"e0127310","DOI":"10.1371\/journal.pone.0127310","volume":"10","author":"B Cunniff","year":"2015","unstructured":"Cunniff, B. et al. Disabling mitochondrial peroxide metabolism via combinatorial targeting of peroxiredoxin 3 as an effective therapeutic approach for malignant mesothelioma. PLoS One 10, e0127310 (2015).","journal-title":"PLoS One"},{"key":"75153_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.redox.2014.11.003","volume":"3","author":"B Cunniff","year":"2014","unstructured":"Cunniff, B. et al. Peroxiredoxin 3 levels regulate a mitochondrial redox setpoint in malignant mesothelioma cells. Redox Biol. 3, 79\u201387 (2014).","journal-title":"Redox Biol."},{"key":"75153_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/jcp.24232","volume":"228","author":"B Cunniff","year":"2013","unstructured":"Cunniff, B. et al. Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells. J. Cell Physiol. 228, 835\u2013845 (2013).","journal-title":"J. Cell Physiol."},{"key":"75153_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/bjc.1998.182","volume":"77","author":"K Kinnula","year":"1998","unstructured":"Kinnula, K. et al. Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. Br. J. Cancer 77, 1097\u20131102 (1998).","journal-title":"Br. J. Cancer"},{"key":"75153_CR13","doi-asserted-by":"publisher","first-page":"e39404","DOI":"10.1371\/journal.pone.0039404","volume":"7","author":"K Newick","year":"2012","unstructured":"Newick, K. et al. Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PLoS One 7, e39404 (2012).","journal-title":"PLoS One"},{"key":"75153_CR14","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1111\/j.1742-4658.2009.06985.x","volume":"276","author":"A Hall","year":"2009","unstructured":"Hall, A., Karplus, P. A. & Poole, L. B. Typical 2-Cys peroxiredoxins-structures, mechanisms and functions. FEBS J. 276, 2469\u20132477 (2009).","journal-title":"FEBS J."},{"key":"75153_CR15","doi-asserted-by":"publisher","first-page":"e1008202","DOI":"10.1371\/journal.pcbi.1008202","volume":"16","author":"KT Stein","year":"2020","unstructured":"Stein, K. T. et al. Kinetic modeling of H2O2 dynamics in the mitochondria of HeLa cells. PLoS Comput Biol. 16, e1008202 (2020).","journal-title":"PLoS Comput Biol."},{"key":"75153_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0968-0004(02)00003-8","volume":"28","author":"ZA Wood","year":"2003","unstructured":"Wood, Z. A. et al. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 28, 32\u201340 (2003).","journal-title":"Trends Biochem Sci."},{"key":"75153_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/path.1042","volume":"196","author":"VL Kinnula","year":"2002","unstructured":"Kinnula, V. L. et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J. Pathol. 196, 316\u2013323 (2002).","journal-title":"J. Pathol."},{"key":"75153_CR18","doi-asserted-by":"crossref","unstructured":"Nelson, K. J., et al., Unique cellular and biochemical features of human mitochondrial peroxiredoxin 3 establish the molecular basis for its specific reaction with thiostrepton. Antioxidants (Basel) 10, 150 (2021).","DOI":"10.3390\/antiox10020150"},{"key":"75153_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cmet.2020.02.003","volume":"31","author":"VV Pak","year":"2020","unstructured":"Pak, V. V. et al. Ultrasensitive genetically encoded indicator for hydrogen peroxide identifies roles for the oxidant in cell migration and mitochondrial function. Cell Metab. 31, 642\u2013653 e6 (2020).","journal-title":"Cell Metab."},{"key":"75153_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.bcp.2012.01.027","volume":"83","author":"S Qiao","year":"2012","unstructured":"Qiao, S. et al. Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes. Biochem Pharm. 83, 1229\u20131240 (2012).","journal-title":"Biochem Pharm."},{"key":"75153_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 e16 (2017).","journal-title":"Cell"},{"key":"75153_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21798-w","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat. Commun. 12, 1751 (2021).","journal-title":"Nat. Commun."},{"key":"75153_CR23","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48, W488\u2013W493 (2020).","journal-title":"Nucleic Acids Res."},{"key":"75153_CR24","doi-asserted-by":"publisher","first-page":"e02523","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e02523 (2014).","journal-title":"Elife"},{"key":"75153_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273\u2013285 (2017).","journal-title":"Cell"},{"key":"75153_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ab.2013.08.013","volume":"443","author":"B Cunniff","year":"2013","unstructured":"Cunniff, B. et al. A direct and continuous assay for the determination of thioredoxin reductase activity in cell lysates. Anal. Biochem 443, 34\u201340 (2013).","journal-title":"Anal. Biochem"},{"key":"75153_CR27","first-page":"682","volume":"1","author":"L Nonn","year":"2003","unstructured":"Nonn, L., Berggren, M. & Powis, G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol. Cancer Res 1, 682\u2013689 (2003).","journal-title":"Mol. Cancer Res"},{"key":"75153_CR28","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s13277-013-0769-0","volume":"34","author":"XY Wang","year":"2013","unstructured":"Wang, X. Y., Wang, H. J. & Li, X. Q. Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumour Biol. 34, 2275\u20132281 (2013).","journal-title":"Tumour Biol."},{"key":"75153_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R. et al. The present and future of the cancer dependency map. Nat. Rev. Cancer 25, 59\u201373 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"75153_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/ars.2010.3766","volume":"16","author":"JY Huh","year":"2012","unstructured":"Huh, J. Y. et al. Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid. Redox Signal 16, 229\u2013243 (2012).","journal-title":"Antioxid. Redox Signal"},{"key":"75153_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.bbrc.2007.02.022","volume":"355","author":"L Li","year":"2007","unstructured":"Li, L. et al. Increased susceptibility of MER5 (peroxiredoxin III) knockout mice to LPS-induced oxidative stress. Biochem Biophys. Res. Commun. 355, 715\u2013721 (2007).","journal-title":"Biochem Biophys. Res. Commun."},{"key":"75153_CR32","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/bjc.2013.396","volume":"109","author":"HC Whitaker","year":"2013","unstructured":"Whitaker, H. C. et al. Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. Br. J. Cancer 109, 983\u2013993 (2013).","journal-title":"Br. J. Cancer"},{"key":"75153_CR33","doi-asserted-by":"publisher","first-page":"7163","DOI":"10.3390\/ijms12107163","volume":"12","author":"IS Song","year":"2011","unstructured":"Song, I. S. et al. Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J. Mol. Sci. 12, 7163\u20137185 (2011).","journal-title":"Int J. Mol. Sci."},{"key":"75153_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(24)00111-5","volume":"12","author":"KG Blyth","year":"2024","unstructured":"Blyth, K. G. et al. Leveraging the pleural space for anticancer therapies in pleural mesothelioma. Lancet Respir. Med 12, 476\u2013483 (2024).","journal-title":"Lancet Respir. Med"},{"key":"75153_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000360769","volume":"88","author":"R Bhatnagar","year":"2014","unstructured":"Bhatnagar, R. & Maskell, N. A. Indwelling pleural catheters. Respiration 88, 74\u201385 (2014).","journal-title":"Respiration"},{"key":"75153_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q. et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct. Target Ther. 9, 55 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"75153_CR37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula, P., Zhuang, L. & Gan, B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12, 599\u2013620 (2021).","journal-title":"Protein Cell"},{"key":"75153_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aaw9872","volume":"368","author":"MA Badgley","year":"2020","unstructured":"Badgley, M. A. et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368, 85\u201389 (2020).","journal-title":"Science"},{"key":"75153_CR39","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/0008-5472.CAN-18-3037","volume":"79","author":"T Liu","year":"2019","unstructured":"Liu, T. et al. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res 79, 1913\u20131924 (2019).","journal-title":"Cancer Res"},{"key":"75153_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39401-9","volume":"14","author":"Y Yan","year":"2023","unstructured":"Yan, Y. et al. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nat. Commun. 14, 3673 (2023).","journal-title":"Nat. Commun."},{"key":"75153_CR41","doi-asserted-by":"crossref","unstructured":"Rahim, S. & Uren, A. A real-time electrical impedance based technique to measure invasion of endothelial cell monolayer by cancer cells. J. Vis. Exp. 50, 2792 (2011).","DOI":"10.3791\/2792"},{"key":"75153_CR42","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet 43, 1022\u20131025 (2011).","journal-title":"Nat. Genet"},{"key":"75153_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet 48, 407\u2013416 (2016).","journal-title":"Nat. Genet"},{"key":"75153_CR44","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","volume":"127","author":"S Hiltbrunner","year":"2022","unstructured":"Hiltbrunner, S. et al. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br. J. Cancer 127, 1997\u20132005 (2022).","journal-title":"Br. J. Cancer"},{"key":"75153_CR45","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"75153_CR46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/15384101.2019.1597506","volume":"18","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y., Koppula, P. & Gan, B. Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell Cycle 18, 773\u2013783 (2019).","journal-title":"Cell Cycle"},{"key":"75153_CR47","first-page":"100672","volume":"5","author":"D Xu","year":"2024","unstructured":"Xu, D. et al. BAP1 deficiency inflames the tumor immune microenvironment and is a candidate biomarker for immunotherapy response in malignant pleural mesothelioma. JTO Clin. Res Rep. 5, 100672 (2024).","journal-title":"JTO Clin. Res Rep."},{"key":"75153_CR48","doi-asserted-by":"crossref","unstructured":"Fahey, C. C. & Davis, I. J. SETting the stage for cancer development: SETD2 and the consequences of lost methylation. Cold Spring Harb. Perspect Med. 7, a026468 (2017).","DOI":"10.1101\/cshperspect.a026468"},{"key":"75153_CR49","doi-asserted-by":"publisher","first-page":"102102","DOI":"10.1016\/j.jbc.2022.102102","volume":"298","author":"S Guo","year":"2022","unstructured":"Guo, S. et al. Interplay between H3K36me3, methyltransferase SETD2, and mismatch recognition protein MutSalpha facilitates processing of oxidative DNA damage in human cells. J. Biol. Chem. 298, 102102 (2022).","journal-title":"J. Biol. Chem."},{"key":"75153_CR50","doi-asserted-by":"publisher","first-page":"e02482","DOI":"10.7554\/eLife.02482","volume":"3","author":"S Carvalho","year":"2014","unstructured":"Carvalho, S. et al. SETD2 is required for DNA double-strand break repair and activation of the 53-mediated checkpoint. Elife 3, e02482 (2014).","journal-title":"Elife"},{"key":"75153_CR51","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI124049","volume":"130","author":"K Hu","year":"2020","unstructured":"Hu, K. et al. Suppression of the SLC7A11\/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J. Clin. Invest 130, 1752\u20131766 (2020).","journal-title":"J. Clin. Invest"},{"key":"75153_CR52","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","volume":"8","author":"S Papa","year":"2013","unstructured":"Papa, S. et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J. Thorac. Oncol. 8, 783\u2013787 (2013).","journal-title":"J. Thorac. Oncol."},{"key":"75153_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03998-w","volume":"12","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 12, 698 (2021).","journal-title":"Cell Death Dis."},{"key":"75153_CR54","doi-asserted-by":"publisher","first-page":"eady4492","DOI":"10.1126\/sciadv.ady4492","volume":"11","author":"KJ Nelson","year":"2025","unstructured":"Nelson, K. J. et al. Mechanism-based peroxiredoxin 3 inhibitors exploit a covalent warhead for cancer therapy. Sci. Adv. 11, eady4492 (2025).","journal-title":"Sci. Adv."},{"key":"75153_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"75153_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"75153_CR57","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. bioRxiv, 060012. https:\/\/doi.org\/10.1101\/060012 (2021)","DOI":"10.1101\/060012"},{"key":"75153_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49842-5","volume":"15","author":"M Zhang","year":"2024","unstructured":"Zhang, M. et al. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma. Nat. Commun. 15, 7187 (2024).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75153-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:03:05Z","timestamp":1784019785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75153-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75153"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75153-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.M., B.C., G.N.N., and D.A.F. are paid consultants and B.C. and N.H.H. are equity holders in RS Oncology, LLC. K.G.B. has received consultancy fees and institutional funding for research from RS Oncology. B.C. is an inventor on a patent (WO2020142782A1) submitted by RS Oncology, University of Vermont, and Wake Forest University Health Sciences that covers use of an intact thiostrepton formulation for the treatment of cancer. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5929"}}